2.56 USD
+0.02
0.79%
Updated Aug 26, 9:52 AM EDT
1 day
0.79%
5 days
-3.40%
1 month
-13.80%
3 months
-5.88%
6 months
-39.34%
Year to date
-5.54%
1 year
-42.98%
5 years
-88.14%
10 years
-88.14%
 

About: Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.

Employees: 157

0
Funds holding %
of 7,430 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

64% more repeat investments, than reductions

Existing positions increased: 54 | Existing positions reduced: 33

7% more capital invested

Capital invested by funds: $215M [Q1] → $229M (+$14.7M) [Q2]

2.8% more ownership

Funds ownership: 67.17% [Q1] → 69.97% (+2.8%) [Q2]

9% less funds holding

Funds holding: 140 [Q1] → 127 (-13) [Q2]

33% less call options, than puts

Call options by funds: $862K | Put options by funds: $1.29M

38% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 24

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$5.89
130%
upside
Avg. target
$6.95
171%
upside
High target
$8
213%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
Morgan Stanley
Vikram Purohit
130%upside
$5.89
Overweight
Maintained
18 Aug 2025
Needham
Gil Blum
213%upside
$8
Buy
Maintained
13 Aug 2025

Financial journalist opinion

Based on 8 articles about ABSI published over the past 30 days

Neutral
GlobeNewsWire
17 hours ago
Absci Expands ABS-201 Scientific Advisory Board with Addition of Leading Dermatology Experts Dr. Rodney Sinclair and Dr. David Goldberg
World-renowned experts will guide the clinical development of ABS-201, a therapeutic antibody entering clinical trials for the treatment of androgenetic alopecia. World-renowned experts will guide the clinical development of ABS-201, a therapeutic antibody entering clinical trials for the treatment of androgenetic alopecia.
Absci Expands ABS-201 Scientific Advisory Board with Addition of Leading Dermatology Experts Dr. Rodney Sinclair and Dr. David Goldberg
Neutral
GlobeNewsWire
6 days ago
Absci to Participate in Upcoming Investor Conferences
VANCOUVER, Wash. and NEW YORK, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, today announced the company will be participating in the following upcoming investor conferences:
Absci to Participate in Upcoming Investor Conferences
Neutral
Seeking Alpha
1 week ago
Absci Corporation (ABSI) Q2 2025 Earnings Call Transcript
Absci Corporation (NASDAQ:ABSI ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Alexander Khan - VP of Finance & Head of Investor Relations Christian Stegmann - Senior Vice President of Drug Creation Sean McClain - Founder, CEO, President & Director Zachariah Jonasson - Chief Business Officer & CFO Conference Call Participants Alexander Xenakis - Unidentified Company Truist Securities - Unidentified Company Arseniy Shabashvili - Guggenheim Securities, LLC, Research Division Brendan Mychal Smith - TD Cowen, Research Division Debanjana Chatterjee - JonesTrading Institutional Services, LLC, Research Division Gil Joseph Blum - Needham & Company, LLC, Research Division Morgan K. Gryga - Morgan Stanley, Research Division Steven Craig Dechert - KeyBanc Capital Markets Inc., Research Division Swayampakula Ramakanth - H.C.
Absci Corporation (ABSI) Q2 2025 Earnings Call Transcript
Negative
Zacks Investment Research
1 week ago
Absci Corporation (ABSI) Reports Q2 Loss, Misses Revenue Estimates
Absci Corporation (ABSI) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.22 per share a year ago.
Absci Corporation (ABSI) Reports Q2 Loss, Misses Revenue Estimates
Neutral
GlobeNewsWire
1 week ago
Absci Reports Business Updates and Second Quarter 2025 Financial and Operating Results
Strengthened balance sheet raising approximately $64 million in gross proceeds in July 2025; cash, cash equivalents, and short-term investments now sufficient to fund operations into the first half of 2028
Absci Reports Business Updates and Second Quarter 2025 Financial and Operating Results
Neutral
GlobeNewsWire
2 weeks ago
Almirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target
BARCELONA, Spain and VANCOUVER, Wash., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Almirall (BME: ALM), a global biopharmaceutical company focused on medical dermatology, and Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, today announced the expansion of their ongoing AI Drug Discovery collaboration with Almirall's selection of a second target aimed at dermatological indications.
Almirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target
Positive
Zacks Investment Research
2 weeks ago
Absci Corporation (ABSI) Expected to Beat Earnings Estimates: Should You Buy?
ABSCI CORP (ABSI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Absci Corporation (ABSI) Expected to Beat Earnings Estimates: Should You Buy?
Neutral
GlobeNewsWire
3 weeks ago
Absci to Report Business Updates and Second Quarter 2025 Financial and Operating Results on August 12, 2025
VANCOUVER, Wash. and NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative design, today announced the company will report business updates and financial and operating results for the second quarter 2025 after market close on Tuesday, August 12, 2025.
Absci to Report Business Updates and Second Quarter 2025 Financial and Operating Results on August 12, 2025
Negative
Benzinga
1 month ago
Intel, Absci, AST SpaceMobile And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Friday.
Intel, Absci, AST SpaceMobile And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Neutral
GlobeNewsWire
1 month ago
Absci Announces Pricing of Public Offering of Common Stock
VANCOUVER, Wash., July 24, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI) (“Absci”), a clinical-stage biopharmaceutical company advancing potential breakthrough therapeutics designed with generative AI, today announced the pricing of an underwritten public offering of 16,670,000 shares of its common stock at a public offering price of $3.00 per share, before deducting underwriting discounts and commissions. In addition, Absci has granted the underwriters a 30-day option to purchase up to an additional 2,500,500 shares of its common stock on the same terms and conditions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $50 million, excluding any exercise of the underwriters' option to purchase additional shares. All of the shares in the offering are to be sold by Absci.
Absci Announces Pricing of Public Offering of Common Stock
Charts implemented using Lightweight Charts™